Recs

1

3 Ingredients for an Obesity Drug Blockbuster

By | More Articles
January 8, 2013 | Comments (2)

VIVUS (NASDAQ: VVUS  ) partially redeemed itself to shareholders yesterday after releasing impressive prescription data for its obesity drug Qsymia -- but it'll take more than that for this drug to reach blockbuster status. To make matters worse, the Belviq launch by VIVUS' rival Arena Pharmaceuticals (NASDAQ: ARNA  ) is just around the corner and could put a wet towel on VIVUS' recent progress if it proves to be successful.

However, the battle for dominance in the obesity space is just getting started. Focusing on VIVUS in this video, health care analyst Max Macaluso identifies three areas that the company rapidly needs to improve if it hopes to dominate this therapeutic space.

What's inside Supernova?
If you're an investor looking for big long term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 09, 2013, at 11:41 AM, feelinIrie wrote:

    Maybe VVUS should release to it's shareholders how many of those "scripts" were actually paid for and not part of the "free trial" program.

  • Report this Comment On January 09, 2013, at 11:56 AM, bmc007 wrote:

    IMHO, it's game over for Vivus and Qsymia. Only a matter of time before Belviq is approved in Europe.

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 2185277, ~/Articles/ArticleHandler.aspx, 5/23/2013 9:44:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 15,228.92 -78.25 -0.51%
S&P 500 1,638.59 -16.76 -1.01%
NASD 3,435.94 -27.36 -0.79%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/22/2013 4:00 PM
VVUS $13.52 Up +0.36 +0.00%
VIVUS, Inc. CAPS Rating: **
ESRX $62.49 Up +1.18 +0.00%
Express Scripts CAPS Rating: ****
ARNA $7.92 Down -0.07 +0.00%
Arena Pharmaceutic… CAPS Rating: **
AET $59.53 Down -0.74 +0.00%
Aetna, Inc. CAPS Rating: ***

Advertisement